共 50 条
- [31] Phase I/II study investigating safety, tolerability, pharmacokinetics, and preliminary antitumor activity of anti-PD-L1 monoclonal antibody BGB-A333 alone and in combination with anti-PD-1 monoclonal antibody tislelizumab in patients with advanced solid tumorsANNALS OF ONCOLOGY, 2018, 29 : 146 - 146Desai, J.Voskoboynik, M.Markman, B.Hou, J.Zeng, D.Meniawy, T.
- [32] A first-in-human phase I study of the anti-PD-1 antibody PDR001 in patients with advanced solid tumorsJOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)Naing, AungGelderblom, HansGainor, Justin F.Forde, Patrick M.Butler, MarcusLin, Chia-ChiSharma, Sunilde Olza, Maria OchoaSchellens, Jan H. M.Soria, Jean-CharlesTaylor, Matthew H.Silva, Antonio P.Li, ZhonggaiBilic, SanelaCameron, ScottInfante, Jeffrey R.
- [33] Safety and efficacy of YBL-006, an anti-PD-1 monoclonal antibody in advanced solid tumors: A phase I study.JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)Oh, Do-YounPark, John J.Lee, Keun WookKim, Seung TaeSriuranpong, ViroteRha, Sun YoungYoo, ChanghoonKeam, BhumsukSabanathan, DhanushaKim, Se HyunPark, Joon OhParinyanitikul, NapaKim, Min HwanKim, Kyu-PyoKim, MyungsukYoon, JaebongLee, Han SeungOck, Chan-Young
- [34] A phase 1/2 study of retifanlimab (INCMGA00012, Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) combination therapy in patients (Pts) with advanced solid tumorsJOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)Hamid, OmidGutierrez, MartinMehmi, InderjitDudzisz-Sledz, MonikaHoyle, Paul EdwardWei, WendyPowderly, John D.
- [35] Clinical outcomes of a new anti-PD-1 antibody in the treatment of solid tumors in one centerEUROPEAN JOURNAL OF IMMUNOLOGY, 2019, 49 : 1757 - 1758Fang, X.Chen, Y.Yuan, Y.
- [36] A first-in-human phase 1 study of nofazinlimab, an anti-PD-1 antibody, in advanced solid tumors and in combination with regorafenib in metastatic colorectal cancerBritish Journal of Cancer, 2023, 129 : 1608 - 1618Daphne DayJohn J. ParkJermaine CowardBen MarkmanCharlotte LemechJames C. KuoAmy PrawiraMichael P. BrownSarwan BishnoiDusan KotasekR. Matthew StrotherRasha CosmanRila SuYiding MaZenglian YueHui-han HuRachel WuPeiqi LiArchie N. Tse
- [37] A first-in-human phase 1 study of nofazinlimab, an anti-PD-1 antibody, in advanced solid tumors and in combination with regorafenib in metastatic colorectal cancerBRITISH JOURNAL OF CANCER, 2023, 129 (10) : 1608 - 1618Day, DaphnePark, John J.Coward, JermaineMarkman, BenLemech, CharlotteKuo, James C.Prawira, AmyBrown, Michael P.Bishnoi, SarwanKotasek, DusanStrother, R. MatthewCosman, RashaSu, RilaMa, YidingYue, ZenglianHu, Hui-hanWu, RachelLi, PeiqiTse, Archie N.
- [38] A phase 1 study of serplulimab, a novel humanized monoclonal anti-PD-1 antibody, in patients with advanced solid tumors.JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)Ho, Ching-LiangChao, Tsu-YiChang, Chia LunLin, Hsuan-YuYang, FutangWang, QingyuZhu, Jun
- [39] Efficacy and Safety of Iparomlimab, an Anti-PD-1 Antibody, in Patients with Advanced Solid Tumors: A Phase 1c StudyADVANCES IN THERAPY, 2024, 41 (11) : 4153 - 4171Xiong, JianpingOuyang, WeiweiYang, MengxiangGao, ZhenyuanZhou, HuanLou, HanmeiGuo, YabingXu, ZhongyuanZheng, LingLiu, YingWang, ZhongfengSun, PingNiyazi, HuerxidanWang, JianhuaChen, YanZhang, BaihuiLi, LingyanKang, XiaoyanGuo, Weijian
- [40] Anti-PD-1 monoclonal antibody MEDI0680 in a phase I study of patients with advanced solid malignanciesJOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7 (01):Naing, AungInfante, JeffreyGoel, SanjayBurris, HowardBlack, ChelseaMarshall, ShannonAchour, IkbelBarbee, SusannahMay, RenaMorehouse, ChrisPollizzi, KristenSong, XuyangSteele, KeithElgeioushi, NairouzWalcott, FarzanaKarakunnel, JoysonLoRusso, PatriciaWeise, AmyEder, JosephCurti, BrendanOberst, Michael